US nonprofit research institute contributing nanomaterial risk governance and liver disease biomarker validation to large EU consortia.
RTI Health Sciences is the EU-facing arm of RTI International, a large US nonprofit research institute headquartered in Research Triangle Park, North Carolina. They bring applied health sciences and regulatory science expertise to international research consortia, contributing methods in computational toxicology, epidemiology, biomarker validation, and quantitative risk assessment. In H2020, they have contributed both to nanomaterial safety governance — building risk assessment frameworks and decision-support tools — and to clinical liver disease research through large-scale biomarker validation studies. Their distinctive value is bridging North American regulatory expertise and methodologies with European research programs.
In caLIBRAte (2016-2019), RTI-HS contributed to a next-generation risk governance system covering hazard prediction, exposure modelling, integrated risk assessment, and control banding for nanomaterials.
In LITMUS (2017-2024), RTI-HS participated in a 7-year clinical study testing and validating biomarkers for NAFLD and steatohepatitis (NASH).
caLIBRAte explicitly included decision support and integrated risk assessment components, areas where RTI International has deep institutional expertise.
Exposure modelling was a listed keyword contribution in caLIBRAte, reflecting RTI's long-standing work in occupational and environmental exposure science.
RTI-HS entered H2020 (2016) through the lens of nanotechnology safety — focusing on computational toxicology, risk governance frameworks, exposure modelling, and decision-support tools for industrial nanomaterial hazards. Their second project (2017-2024) pivoted sharply toward clinical health science, specifically the validation of blood-based or imaging biomarkers for non-alcoholic fatty liver disease. This trajectory suggests the organization is not locked into a single domain, but instead deploys its core methodological strength — quantitative evidence synthesis and regulatory-grade validation — across different scientific problems as funding opportunities arise.
RTI-HS appears to be moving away from environmental/regulatory risk science and toward clinical biomarker research, suggesting future collaborations are most likely in disease diagnostics, health technology assessment, or real-world evidence studies.
RTI-HS has never led an H2020 project, always joining as a participant — consistent with a large US institute that contributes defined methodological expertise rather than seeking to coordinate EU consortia. Notably, just 2 projects have generated 81 unique partner relationships across 19 countries, which is only possible by joining very large RIA consortia (typically 20-30+ institutions). This positions them as a high-value specialist node in big networks, not a recurring bilateral collaborator.
With 81 unique partners across 19 countries from only 2 projects, RTI-HS has participated exclusively in large, multi-partner RIA consortia with broad European and transatlantic representation. Their network is wide but shallow — diverse in geography but not built on repeated bilateral partnerships.
RTI-HS is one of very few US-based research institutes registered as an H2020 participant, which immediately makes them valuable for consortia seeking transatlantic reach, access to US regulatory frameworks (FDA, EPA), or North American data cohorts. Their ability to operate credibly in both nanotechnology safety and clinical liver disease research — two quite different domains — signals methodological versatility rather than narrow subject-matter specialization. For a consortium needing rigorous quantitative methods, health economics, or a US institutional partner, RTI-HS is a rare and strategically useful option.
